NYSE:ENZ

Enzo Biochem - ENZ Stock Forecast, Price & News

$2.12

-0.01 (-0.47%)

(As of 09/27/2022 01:48 PM ET)

Add

Compare

Today's Range: $2.12
▼
$2.17
50-Day Range: $2.13
▼
$2.73
52-Week Range: $1.98
▼
$4.15

Volume: 147 shs
Average Volume: 51,927 shs
Market Capitalization: $103.29 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Enzo Biochem MarketRank™ Forecast

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Healthy
1.09% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.77
Based on 3 Articles This Week
Insider Trading: Acquiring Shares
$298,425 Bought Last Quarter
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.50 out of 5 stars

Medical Sector

1010th out of 1,071 stocks

Medical Laboratories Industry

27th out of 29 stocks

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for Enzo Biochem.

3.0

Short Interest

Percentage of Shares Shorted
1.09% of the float of Enzo Biochem has been sold short.
Short Interest Ratio / Days to Cover
Enzo Biochem has a short interest ratio ("days to cover") of 6.1.
Change versus previous month
Short interest in Enzo Biochem has recently decreased by 1.96%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Enzo Biochem does not currently pay a dividend.
Dividend Growth
Enzo Biochem does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ENZ.

2.7

News and Social Media Coverage

News Sentiment
Enzo Biochem has a news sentiment score of 0.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Enzo Biochem this week, compared to 1 article on an average week.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Enzo Biochem insiders have bought more of their company's stock than they have sold. Specifically, they have bought $298,425.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
17.40% of the stock of Enzo Biochem is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
43.29% of the stock of Enzo Biochem is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Enzo Biochem is -16.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Enzo Biochem is -16.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Enzo Biochem has a P/B Ratio of 1.54. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Enzo Biochem (NYSE:ENZ) Stock

Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products segment develops, manufactures, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. This segment also provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Clinical Laboratory Services segment provides molecular and other clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition. It operates a full-service clinical laboratory in Farmingdale, New York; a network of 30 patient service centers in New York and New Jersey; and a free-standing 'STAT' or rapid response laboratories in New York City and Connecticut, as well as a full-service phlebotomy center and an in-house logistics department. The Therapeutics segment develops novel approaches in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. It markets its products and services through its direct sales force and a network of distributors in the United States and internationally. The company was founded in 1976 and is headquartered in New York, New York.

Receive ENZ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enzo Biochem and its competitors with MarketBeat's FREE daily newsletter.

ENZ Stock News Headlines

September 26, 2022 | finance.yahoo.com

Enzo Biochem, Inc. Launches AMPIVIEW™ Gene Expression Platform with First Products Targeting Detection of HPV and SARS-CoV-2

September 19, 2022 | americanbankingnews.com

StockNews.com Begins Coverage on Enzo Biochem (NYSE:ENZ)

September 27, 2022 | Investing Trends (Ad)

How High Can Copper Go?

To power the green revolution, copper demand continues to skyrocket with no end in sight. Prices hit a 10-year high; as copper jumped 79% in the past year. Some analysts are calling for copper to rise another 50-100%! We may be at the beginning of a copper bull run the likes we've never seen before. Just how high can copper go?

September 18, 2022 | americanbankingnews.com

Enzo Biochem (NYSE:ENZ) Share Price Passes Above 200 Day Moving Average of $2.56

August 30, 2022 | finance.yahoo.com

Individual investors account for 33% of Enzo Biochem, Inc.'s (NYSE:ENZ) ownership, while institutions account for 27%

August 11, 2022 | finance.yahoo.com

Enzo Biochem to Launch Monkeypox Testing Services this Week

August 3, 2022 | finance.yahoo.com

Enzo Biochem Appoints Matthew Kupferberg as General Counsel

July 4, 2022 | finance.yahoo.com

Is Enzo Biochem (NYSE:ENZ) A Risky Investment?

September 27, 2022 | Investing Trends (Ad)

How High Can Copper Go?

June 27, 2022 | seekingalpha.com

Enzo Biochem: Activist Pressure Could Finally Lead To A Company Sale

June 11, 2022 | finance.yahoo.com

A Enzo Biochem, Inc. (NYSE:ENZ) insider increased their holdings by 21% last year

June 9, 2022 | finance.yahoo.com

Enzo Biochem Reports Third Quarter Fiscal 2022 Results and Provides Leadership and Corporate Updates Including Engagement of Jefferies as Financial Advisor

June 6, 2022 | finance.yahoo.com

UPDATE -- Enzo Biochem to Report Third Quarter 2022 Financial Results and Business Update on Thursday, June 9th

June 6, 2022 | finance.yahoo.com

UPDATE -- Enzo Biochem to Report Third Quarter 2022 Financial Results and Business Update on Thursday, June 9th

June 5, 2022 | markets.businessinsider.com

The Week Ahead In Biotech (June 5-11): Adcom Test For Novavax, ASCO Presentations, Enzo Biochem Earnings And More

June 2, 2022 | apnews.com

Enzo Biochem to Report Third Quarter 2022 Financial Results and Business Update on Thursday, June 9th

June 2, 2022 | finance.yahoo.com

Enzo Biochem to Report Third Quarter 2022 Financial Results and Business Update on Thursday, June 9th

May 9, 2022 | finance.yahoo.com

Investors in Enzo Biochem (NYSE:ENZ) have unfortunately lost 73% over the last five years

May 4, 2022 | msn.com

Farmingdale's Enzo BioChem Receives LI Association COVID Hero Award

April 19, 2022 | marketwatch.com

Enzo Biochem HPV Test Gets New York State Approval

April 19, 2022 | seekingalpha.com

Enzo Biochem gains on New York approval for test to detect human papillomavirus

April 19, 2022 | finance.yahoo.com

Enzo Biochem Announces New York State Department of Health Approval of HPV Molecular Diagnostic Test

April 12, 2022 | finance.yahoo.com

Enzo Biochem Reports Results of its Annual Meeting of Shareholders

April 6, 2022 | finance.yahoo.com

Enzo Biochem Adjourns Annual Meeting of Shareholders to Complete Vote on Proposal

April 1, 2022 | finance.yahoo.com

Enzo Biochem Adjourns Annual Meeting of Shareholders Until April 8, 2022

March 28, 2022 | seekingalpha.com

Enzo Biochem names Kara Cannon as operating chief

March 28, 2022 | finance.yahoo.com

Enzo Biochem Appoints David Bench and Kara Cannon to New Executive Management Positions

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive ENZ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enzo Biochem and its competitors with MarketBeat's FREE daily newsletter.

ENZ Company Calendar

Last Earnings: 10/15/2019
Today: 9/27/2022
Next Earnings (Estimated): 10/11/2022
Fiscal Year End: 7/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Medical laboratories
Sub-Industry: N/A
Sector: Medical
Current Symbol: NYSE:ENZ
CUSIP: N/A
CIK: 316253
Web: www.enzo.com
Phone: (212) 583-0100
Fax: 212-679-7999
Employees: 451
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($0.13)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $7.88 million
Net Margins: -5.88%
Pretax Margin: -5.88%
Return on Equity: -1.98%
Return on Assets: -1.20%

Debt

Debt-to-Equity Ratio: 0.07
Current Ratio: 2.52
Quick Ratio: 1.92

Sales & Book Value

Annual Sales: $117.73 million
Price / Sales: 0.88
Cash Flow: $0.26 per share
Price / Cash Flow: 8.23
Book Value: $1.41 per share
Price / Book: 1.50

Miscellaneous

Outstanding Shares: 48,720,000
Free Float: 40,243,000
Market Cap: $103.29 million
Optionable: Optionable
Beta: 0.85

Key Executives

Dr. Elazar Rabbani Ph.D. (Age 79)
Co-Founder & Director
Comp: $830.9k

Dr. Dieter Schapfel M.D. (Age 59)
Chief Medical Director of Enzo Clinical Labs
Comp: $404.03k

Mr. Hamid Erfanian (Age 52)
CEO & Director

Mr. David A. Bench
CFO, Sr. VP, Treasurer & Corp. Sec.

Ms. Kara Cannon (Age 53)
Chief Operating Officer

Mr. Matthew Kupferberg
Gen. Counsel

Mr. Bruce A. Dey (Age 64)
VP of Sales & Marketing - Enzo Clinical Labs

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ENZ Stock - Frequently Asked Questions

How have ENZ shares performed in 2022?: Enzo Biochem's stock was trading at $3.21 at the beginning of the year. Since then, ENZ stock has decreased by 33.6% and is now trading at $2.13.
View the best growth stocks for 2022 here.
When is Enzo Biochem's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, October 11th 2022.
View our ENZ earnings forecast.
How were Enzo Biochem's earnings last quarter?: Enzo Biochem, Inc. (NYSE:ENZ) posted its earnings results on Tuesday, October, 15th. The medical research company reported ($0.11) EPS for the quarter, topping analysts' consensus estimates of ($0.14) by $0.03. The medical research company had revenue of $20.92 million for the quarter. Enzo Biochem had a negative trailing twelve-month return on equity of 1.98% and a negative net margin of 5.88%.
What other stocks do shareholders of Enzo Biochem own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Enzo Biochem investors own include OneLife Technologies (OLMM), Gilead Sciences (GILD), OPKO Health (OPK), Teva Pharmaceutical Industries (TEVA), Inovio Pharmaceuticals (INO), AbbVie (ABBV), Pfizer (PFE), Advanced Micro Devices (AMD), Amarin (AMRN) and Micron Technology (MU).

What is Enzo Biochem's stock symbol?: Enzo Biochem trades on the New York Stock Exchange (NYSE) under the ticker symbol "ENZ."
Who are Enzo Biochem's major shareholders?: Enzo Biochem's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (6.19%), Potomac Capital Management Inc. (1.15%), Potomac Capital Management Inc. (1.15%), State Street Corp (0.38%), Virtu Financial LLC (0.06%) and Goldman Sachs Group Inc. (0.04%). Insiders that own company stock include Bradley Louis Radoff, David Bench, Discovery Fund Lp Harbert, Hamid Erfanian, Kara Cannon and Peter J Iv Clemens.
View institutional ownership trends.
How do I buy shares of Enzo Biochem?: Shares of ENZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Enzo Biochem's stock price today?: One share of ENZ stock can currently be purchased for approximately $2.13.
How much money does Enzo Biochem make?: Enzo Biochem (NYSE:ENZ) has a market capitalization of $103.77 million and generates $117.73 million in revenue each year. The medical research company earns $7.88 million in net income (profit) each year or ($0.13) on an earnings per share basis.
How many employees does Enzo Biochem have?: The company employs 451 workers across the globe.
How can I contact Enzo Biochem?: Enzo Biochem's mailing address is 527 Madison Ave., New York NY, 10022. The official website for the company is www.enzo.com. The medical research company can be reached via phone at (212) 583-0100, via email at ir@enzo.com, or via fax at 212-679-7999.

This page (NYSE:ENZ) was last updated on 9/27/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Enzo Biochem - ENZ Stock Forecast, Price & News

Enzo Biochem MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month